Gregory L. Shiferman - 13 Feb 2025 Form 4 Insider Report for Sage Therapeutics, Inc. (SAGE)

Role
Senior Vice President, General Counsel and Secretary
Signature
Brandon Marsh, attorney in fact for Gregory Shiferman
Issuer symbol
SAGE
Transactions as of
13 Feb 2025
Net transactions value
-$4,502
Form type
4
Filing time
14 Feb 2025, 16:26:50 UTC
Previous filing
21 Jan 2025
Next filing
25 Feb 2025
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction SAGE Common Stock Tax liability $2,700 -376 -1.1% $7.18 33,512 13 Feb 2025 Direct F1
transaction SAGE Common Stock Tax liability $1,802 -251 -0.75% $7.18 33,261 13 Feb 2025 Direct F2
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 On February 13, 2025, the reporting person vested 1,125 shares of time-based restricted stock units (RSUs) granted on February 13, 2023 under the Sage Therapeutics, Inc. 2014 Stock Option and Incentive Plan. This grant vests 25% on each grant anniversary date over four years. Represents shares withheld to satisfy tax withholding obligations on the vesting of restricted stock units.
F2 On February 13, 2025, the reporting person vested 750 shares of time-based restricted stock units (RSUs) granted on February 13, 2024 under the Sage Therapeutics, Inc. 2014 Stock Option and Incentive Plan. This grant vests 25% on each grant anniversary date over four years. Represents shares withheld to satisfy tax withholding obligations on the vesting of restricted stock units.

Remarks:

Senior Vice President, General Counsel and Secretary